The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia. / Pazzi, Paolo; Celliers, Anri; du Plessis, Elizabeth C.; Kristensen, Annemarie T.; Goddard, Amelia.

In: Veterinary and Comparative Oncology, Vol. 20, No. 1, 2022, p. 154-163.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Pazzi, P, Celliers, A, du Plessis, EC, Kristensen, AT & Goddard, A 2022, 'The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia', Veterinary and Comparative Oncology, vol. 20, no. 1, pp. 154-163. https://doi.org/10.1111/vco.12757

APA

Pazzi, P., Celliers, A., du Plessis, E. C., Kristensen, A. T., & Goddard, A. (2022). The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia. Veterinary and Comparative Oncology, 20(1), 154-163. https://doi.org/10.1111/vco.12757

Vancouver

Pazzi P, Celliers A, du Plessis EC, Kristensen AT, Goddard A. The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia. Veterinary and Comparative Oncology. 2022;20(1):154-163. https://doi.org/10.1111/vco.12757

Author

Pazzi, Paolo ; Celliers, Anri ; du Plessis, Elizabeth C. ; Kristensen, Annemarie T. ; Goddard, Amelia. / The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia. In: Veterinary and Comparative Oncology. 2022 ; Vol. 20, No. 1. pp. 154-163.

Bibtex

@article{54832f82cb8d4ff48184ef38d48088b8,
title = "The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia",
abstract = "Macroscopic thromboembolic disease has been associated with canine neoplasia, whereas prevalence studies of concurrent microthrombi and tumour-cell emboli are lacking. This retrospective study investigated microthrombi and tumour cell emboli by reviewing pathology records of dogs diagnosed with lymphoma, sarcoma, carcinoma and mast cell tumours with a concurrent description of thrombi or emboli. Pathology reports and medical records of cases with either tumour biopsies and/or post mortems with a diagnosis of neoplasia were reviewed for the presence of microthrombi, macrothrombi and/or tumour-cell emboli and the association with tumour type. Of the 28 895 canine cases in the database, 21 252 (73.5%) were antemortem biopsy specimens and 7643 were post mortems (26.5%); 2274 solid tumours were identified, 2107 (92.7%) were antemortem biopsy diagnoses and 167 (7.3%) were post mortem diagnoses. The prevalence of solid tumour types in the database (28 895 cases) was 872 (3.0%) lymphoma, 722 (2.5%) sarcoma, 455 (1.6%) carcinoma and 225 (0.8%) mast cell tumour. The prevalence of microthrombi associated with these tumours was 58/2274 (2.6%). Intra-tumoral microthrombi were reported in 53/2274 (2.3%) cases, the majority in sarcomas (37/53, 69.8%). No macrothrombi were reported. Tumour-cell emboli were identified in 39/2274 (1.7%) cases, 31/39 (79.5%) were extra-tumoral or distant emboli, and carcinoma the most commonly associated tumour (29/39; 74.4%). Microthrombi were reported in 2.6% of cases, the majority in sarcomas and tumour-cell emboli were identified in 1.7% of cases, the majority carcinomas. Prospective investigations are necessary to explore the potential clinical and prognostic implications of microthrombi and tumour-cell emboli in canine neoplasia.",
keywords = "cancer, clot, emboli, metastasis",
author = "Paolo Pazzi and Anri Celliers and {du Plessis}, {Elizabeth C.} and Kristensen, {Annemarie T.} and Amelia Goddard",
year = "2022",
doi = "10.1111/vco.12757",
language = "English",
volume = "20",
pages = "154--163",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5810",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - The prevalence of intra-tumoral and distant thrombi, as well as tumour-cell emboli in canine neoplasia

AU - Pazzi, Paolo

AU - Celliers, Anri

AU - du Plessis, Elizabeth C.

AU - Kristensen, Annemarie T.

AU - Goddard, Amelia

PY - 2022

Y1 - 2022

N2 - Macroscopic thromboembolic disease has been associated with canine neoplasia, whereas prevalence studies of concurrent microthrombi and tumour-cell emboli are lacking. This retrospective study investigated microthrombi and tumour cell emboli by reviewing pathology records of dogs diagnosed with lymphoma, sarcoma, carcinoma and mast cell tumours with a concurrent description of thrombi or emboli. Pathology reports and medical records of cases with either tumour biopsies and/or post mortems with a diagnosis of neoplasia were reviewed for the presence of microthrombi, macrothrombi and/or tumour-cell emboli and the association with tumour type. Of the 28 895 canine cases in the database, 21 252 (73.5%) were antemortem biopsy specimens and 7643 were post mortems (26.5%); 2274 solid tumours were identified, 2107 (92.7%) were antemortem biopsy diagnoses and 167 (7.3%) were post mortem diagnoses. The prevalence of solid tumour types in the database (28 895 cases) was 872 (3.0%) lymphoma, 722 (2.5%) sarcoma, 455 (1.6%) carcinoma and 225 (0.8%) mast cell tumour. The prevalence of microthrombi associated with these tumours was 58/2274 (2.6%). Intra-tumoral microthrombi were reported in 53/2274 (2.3%) cases, the majority in sarcomas (37/53, 69.8%). No macrothrombi were reported. Tumour-cell emboli were identified in 39/2274 (1.7%) cases, 31/39 (79.5%) were extra-tumoral or distant emboli, and carcinoma the most commonly associated tumour (29/39; 74.4%). Microthrombi were reported in 2.6% of cases, the majority in sarcomas and tumour-cell emboli were identified in 1.7% of cases, the majority carcinomas. Prospective investigations are necessary to explore the potential clinical and prognostic implications of microthrombi and tumour-cell emboli in canine neoplasia.

AB - Macroscopic thromboembolic disease has been associated with canine neoplasia, whereas prevalence studies of concurrent microthrombi and tumour-cell emboli are lacking. This retrospective study investigated microthrombi and tumour cell emboli by reviewing pathology records of dogs diagnosed with lymphoma, sarcoma, carcinoma and mast cell tumours with a concurrent description of thrombi or emboli. Pathology reports and medical records of cases with either tumour biopsies and/or post mortems with a diagnosis of neoplasia were reviewed for the presence of microthrombi, macrothrombi and/or tumour-cell emboli and the association with tumour type. Of the 28 895 canine cases in the database, 21 252 (73.5%) were antemortem biopsy specimens and 7643 were post mortems (26.5%); 2274 solid tumours were identified, 2107 (92.7%) were antemortem biopsy diagnoses and 167 (7.3%) were post mortem diagnoses. The prevalence of solid tumour types in the database (28 895 cases) was 872 (3.0%) lymphoma, 722 (2.5%) sarcoma, 455 (1.6%) carcinoma and 225 (0.8%) mast cell tumour. The prevalence of microthrombi associated with these tumours was 58/2274 (2.6%). Intra-tumoral microthrombi were reported in 53/2274 (2.3%) cases, the majority in sarcomas (37/53, 69.8%). No macrothrombi were reported. Tumour-cell emboli were identified in 39/2274 (1.7%) cases, 31/39 (79.5%) were extra-tumoral or distant emboli, and carcinoma the most commonly associated tumour (29/39; 74.4%). Microthrombi were reported in 2.6% of cases, the majority in sarcomas and tumour-cell emboli were identified in 1.7% of cases, the majority carcinomas. Prospective investigations are necessary to explore the potential clinical and prognostic implications of microthrombi and tumour-cell emboli in canine neoplasia.

KW - cancer

KW - clot

KW - emboli

KW - metastasis

U2 - 10.1111/vco.12757

DO - 10.1111/vco.12757

M3 - Journal article

C2 - 34314552

VL - 20

SP - 154

EP - 163

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5810

IS - 1

ER -

ID: 275878556